The most widely used medications for the treatment of osteoporosis are currently
bisphosphonates (BPs) and denosumab (Dmab). Both are antiresorptives, thus targeting the …

Denosumab is a receptor activator of nuclear factor kappa-Β ligand inhibitor, which
suppresses the bone resorption process to preserve bone mass. It is usually recommended …

Bone remodeling consists of resorption by osteoclasts (OCs) and formation by osteoblasts
(OBs). Precise coordination of these activities is required for the resorbed bone to be …

Purpose Prior osteoporosis therapies may affect the skeletal response to denosumab. We
compared the effect of denosumab (60 mg every 6 months for 12 months) on bone mineral …

Effects of osteoporosis drugs on proximal femur cortical and trabecular bone were studied
using dual-energy x-ray absorptiometry (DXA)-based 3D modeling method. Changes …

Background/objective Osteoporosis is a global health concern with an increasing
prevalence worldwide. Denosumab is an antiresoptive agent that has been demonstrated to …

Introduction: Denosumab is a monoclonal antibody that received approval by the FDA for the
treatment of osteoporosis in 2010. Available higher level research evidence concerns the …

Denosumab is a human monoclonal antibody that neutralizes RANKL, a cytokine able to
interact with the RANK receptor on preosteoclasts and osteoclasts, decreasing their …

摘要目的: 从循证医学角度探讨绝经后骨质疏松(POP) 患者序贯治疗后应用地舒单抗对骨密度和
骨标志物的影响. 方法: 全面检索万方数据库, 维普数据库, 中国知网, 中国生物医学文献数据库 …

Una paciente con osteoporosis había sido tratada por 4 años con ibandronato oral, luego
por 1 año con ranelato de estroncio, y finalmente por 4 años con denosumab. En vista de la …